Chronic Lymphocytic Leukemia

The treatment paradigm for chronic lymphocytic leukemia has expanded beyond continuous treatment with BTK inhibitors with the addition of the time-limited regimen of venetoclax plus obinutuzumab.

R. Gregory Bociek, MD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

The progress made with novel combination regimens coupled with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Kerry A, Rogers, MD, discusses the rationale behind the phase 1b study of VAY736 combined with ibrutinib in patients with chronic lymphocytic leukemia and the next steps for this research.

R. Gregory Bociek, MD, discusses the evolving role of prognostic factors in chronic lymphocytic leukemia.

Fixed-duration treatment that leads to deep treatment-free remissions has become the prioritized strategy for patients with chronic lymphocytic leukemia, made possible by agents such as venetoclax, umbralisib, and lisocabtagene maraleucel.

Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.

Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.

Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses research efforts that are evaluating the use of venetoclax and obinutuzumab in patients with chronic lymphocytic leukemia.

Feburary 23, 2021 — The addition of the anti-CD20 monoclonal antibody ublituximab to ibrutinib led to a statistically higher overall response rate over ibrutinib alone with acceptable safety in patients with relapsed/refractory, high-risk, chronic lymphocytic leukemia.

R. Gregory Bociek, MD, discusses the evolving role of chemoimmunotherapy in chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the potential for CAR T-cell therapy in patients with high-risk chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.

Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, explaines how she navigates among the options available in the frontline setting for patients with CLL and highlighted ongoing research efforts of interest.

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.